Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014
October 04 2016 - 5:00PM
Business Wire
Two Patents of a Family Claiming the Basic
Uses of Chimeric Restriction Nucleases for Gene Editing in Any Type
of Cells
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART), today
announced the issuance of U.S. patent 9,458,439 – which claims gene
inactivation by use of chimeric restriction endonucleases. This
patent granted by the USPTO to the Institut Pasteur and Boston
Children's Hospital naming Dr. André Choulika and Pr. Richard C.
Mulligan as co-inventors, is exclusively licensed to Cellectis.
This issued U.S. patent 9,458,439 claims the method of
introducing chromosomal modifications at a locus by induction of
double-stranded DNA cleavage using a chimeric restriction
endonuclease and non-homologous end joining recombination (NHEJ).
This pivotal invention is at the basis of current nuclease-based
precise gene inactivation techniques using chimeric restriction
endonuclease such as Cas9/CRISPR (and related families), Zinc
finger Nucleases, TAL-Effector Nucleases, Mega-TALEs, some
Meganucleases i.e. endonucleases generated by the juxtaposition of
specific DNA binding sequences and DNA cleavage domains with a
recognition site of at least 12 base pairs. This technology is
universal as it can be applied to any types of cells, including
human, animal, plant cells or microorganisms.
This new patent follows U.S. patent 8,921,332 issued on December
30th, 2014, which claims the use of chimeric restriction
endonucleases for directing chromosomal gene editing in cells by
homologous recombination.
This new patent complements Cellectis’ strong portfolio of gene
editing technologies that are implemented in its CAR T-cell product
candidates, as well as within its Minnesota-based agricultural
biotechnology subsidiary, Calyxt, which develops food products with
healthier characteristics.
The inventors of this patent are Dr. André Choulika, Chairman
& CEO of Cellectis and one of the pioneers in the development
of nuclease-based genome editing technologies, and Professor
Richard C. Mulligan, Mallinckrodt Professor of Genetics, Emeritus,
at Harvard Medical School and a Founding Partner of Sarissa Capital
Management. Professor Mulligan is a world-renowned scientist and
former member of Cellectis’ Board of Directors whose laboratory has
made seminal contributions to the development of fundamental gene
transfer and gene therapy technologies.
Claim 1 of the U.S. patent 9,458,439:
“A method for attenuating or inactivating an endogenous gene of
interest in a cell in vitro comprising:inducing in the cell double
stranded cleavage of chromosomal DNA at a genomic site of interest
in the specific sequence to be modified, wherein the inducing
comprises contacting the genomic site of interest with a chimeric
restriction endonuclease, said chimeric restriction endonuclease
comprising a DNA binding sequence and a DNA cleavage domain, and
said restriction endonuclease recognizing a DNA sequence of at
least 12 bp, wherein said restriction endonuclease is introduced as
a protein or is encoded by a nucleic acid vector that is expressed,
thereby inducing a cellular repair mechanism which leads to highly
efficient recombinational events at said genomic site of interest,
wherein said recombinational events introduce a mutation into said
genomic site of interest, thereby modifying the specific sequence
in the chromosomal DNA of the cell and thereby attenuating or
inactivating an endogenous gene of interest in said cell.”
Claim 1 of the U.S. patent 8,921,332:
“A method of modifying a specific sequence in chromosomal DNA of
a cell in vitro comprising:inducing in the cell double stranded
cleavage of chromosomal DNA at a genomic site of interest in the
specific sequence to be modified, wherein the inducing comprises
contacting the genomic site of interest with a chimeric restriction
endonuclease, said chimeric restriction endonuclease comprising a
DNA binding sequence and a DNA cleavage domain, and said
restriction endonuclease recognizing a DNA sequence of at least 12
bp, wherein said restriction endonuclease is introduced as a
protein or is encoded by a nucleic acid vector that is expressed;
and contacting said cell with a targeting DNA or a nucleic acid
vector encoding said targeting DNA in an amount sufficient to
produce recombination between said targeting DNA and said
chromosomal DNA at the site of interest, wherein said targeting DNA
comprises (1) DNA homologous to the region surrounding the genomic
site of interest and (2) DNA which modifies the specific sequence
upon recombination between said targeting DNA and said chromosomal
DNA, thereby modifying the specific sequence in the chromosomal DNA
of the cell.”
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
16 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases and pioneering electroporation
PulseAgile technology - to create a new generation of
immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets. Cellectis is listed on the Nasdaq market (ticker:
CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out
more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161004006542/en/
CellectisMedia:Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communications,ckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Finance,simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024